Cargando…

The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study

Midostaurin (PKC412A), N-benzoyl-staurosporine, potently inhibits protein kinase C alpha (PKCα), VEGFR2, KIT, PDGFR and FLT3 tyrosine kinases. In mice, midostaurin slows growth and delays lung metastasis of melanoma cell lines. We aimed to test midostaurin's safety, efficacy and biologic activi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Millward, M J, House, C, Bowtell, D, Webster, L, Olver, I N, Gore, M, Copeman, M, Lynch, K, Yap, A, Wang, Y, Cohen, P S, Zalcberg, J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360547/ https://www.ncbi.nlm.nih.gov/pubmed/16969355 http://dx.doi.org/10.1038/sj.bjc.6603331

Ejemplares similares

Activation of HIV-1 expression in latently infected CD4+ T cells by the small molecule PKC412
por: Ao, Zhujun, et al.
Publicado: (2016)

Pre-clinical characterization of PKC412, a multi-kinase inhibitor, against colorectal cancer cells
por: Li, Jian-Ping, et al.
Publicado: (2016)

NEO412: A temozolomide analog with transdermal activity in melanoma in vitro and in vivo
por: Swenson, Steve, et al.
Publicado: (2018)

SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib
por: Karwaciak, Iwona, et al.
Publicado: (2019)

CD133 Is Associated with Increased Melanoma Cell Survival after Multikinase Inhibition
por: Simbulan-Rosenthal, Cynthia M., et al.
Publicado: (2019)

Midostaurin: an emerging treatment for acute myeloid leukemia patients
por: Gallogly, Molly Megan, et al.
Publicado: (2016)

Proceedings of the Euromech Colloquium 412
por: Friedrich, R, et al.
Publicado: (2004)

Clinical potential of midostaurin in advanced systemic mastocytosis
por: Chandesris, Marie Olivia, et al.
Publicado: (2017)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019)

Rare complications of multikinase inhibitor treatment
por: Pitoia, Fabián, et al.
Publicado: (2018)

Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2021)

A Rare Case of Midostaurin-Associated Sweet's Syndrome
por: Yasin, Hesham, et al.
Publicado: (2022)

1126. Three Cases of Neutropenic Enterocolitis Following Midostaurin Administration
por: Carroll, Ryan, et al.
Publicado: (2018)

Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia
por: Gutierrez, Lucas, et al.
Publicado: (2018)

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
por: Kasamon, Yvette L., et al.
Publicado: (2018)

Inositol polyphosphate multikinase signaling in the regulation of metabolism
por: Lee, Joo-Young, et al.
Publicado: (2012)

Multikinase inhibitors use in differentiated thyroid carcinoma
por: Jasim, Sina, et al.
Publicado: (2014)

Daily Management of Patients on Multikinase Inhibitors’ Treatment
por: Colombo, Carla, et al.
Publicado: (2022)

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
por: Tannir, Nizar M., et al.
Publicado: (2017)

Midostaurin potentiates rituximab antitumor activity in Burkitt’s lymphoma by inducing apoptosis
por: Ge, Xiaowen, et al.
Publicado: (2018)

Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study
por: Ji, Ning, et al.
Publicado: (2019)

Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection
por: Abbas, Hussein A, et al.
Publicado: (2019)

Clinically relevant drug interactions with multikinase inhibitors: a review
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2019)

Emerging role of multikinase inhibitors for refractory thyroid cancer
por: Perez, Cesar A, et al.
Publicado: (2012)

Exploring Selectivity of Multikinase Inhibitors across the Human Kinome
por: Miljković, Filip, et al.
Publicado: (2018)

Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib
por: Lin, Tong, et al.
Publicado: (2017)

Targeting RET-rearranged lung cancers with multikinase inhibitors
por: Sabari, Joshua K., et al.
Publicado: (2017)

Timing of multikinase inhibitor initiation in differentiated thyroid cancer
por: Brose, Marcia S, et al.
Publicado: (2017)

Gastrointestinal Tract Homeostasis: The Role of the Inositol Polyphosphate Multikinase
por: Saiardi, Adolfo
Publicado: (2022)

Src, PKCα, and PKCδ are required for αvβ3 integrin-mediated metastatic melanoma invasion
por: Putnam, Andrew J, et al.
Publicado: (2009)

PB1790: ABCB1 AS A POTENTIAL BENEFICIAL TARGET OF MIDOSTAURIN IN ACUTE MYELOID LEUKEMIA
por: Sucha, S., et al.
Publicado: (2022)

The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo
por: Flynn, Sean M., et al.
Publicado: (2019)

Midostaurin as the Most Likely Cause of Bilateral Adrenal Masses in a Patient with Acute Myeloid Leukemia
por: Schutte, Tim, et al.
Publicado: (2022)

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
por: Stemler, Jannik, et al.
Publicado: (2020)

A case of aggressive systemic mastocytosis with bulky lymphadenopathy showing response to midostaurin
por: Sciumè, Mariarita, et al.
Publicado: (2020)

Treatment of Advanced Systemic Mastocytosis with Midostaurin: Practical Guidance for Optimal Therapy and Management
por: Papayannidis, Cristina, et al.
Publicado: (2022)

Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma
por: Miller, Kevin C, et al.
Publicado: (2020)

Metastasis to the oral soft tissues: A review of 412 cases
por: Irani, Soussan
Publicado: (2016)

Oral leukoplakia, a clinical-histopathological study in 412 patients
por: Rubert, Andrea, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p6ujo094acq6eth4p1tlaiirv4